Cel-Sci says Multikine improves long-term survival for head and neck cancer by 33% to 40%

New York, May 23 - Cel-Sci Corp. said long-term survival data from its phase 2 trial of Multikine in patients with head and neck cancer (oral squamous cell carcinoma) showed a 33% to 40% improvement in median survival at 3½ years after surgery.

The survival rate with the drug was compared to the results of 39 trial published between 1987 and 2004.

Cel-Sci derived the data from a follow-up study of 22 patients with advanced untreated primary tumors, who were enrolled in the Multikine phase 2 clinical trial. The Multikine treatment regimen was administered to these patients prior to the standard of care treatment (i.e. surgery and radiation or surgery and chemo-radiation).

Median overall survival (including death from any cause of patients in the trial, even deaths not related to the disease) of the 19 evaluable patients in the follow-up portion of this clinical trial was 63% at a median follow-up of 40 months post-surgery. For the earlier published studies, survival at 3½ years was 47% following standard of care treatment.

Cel-Sci is a Vienna, Va., company developing immune system-based treatments for cancer and infectious diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.